Because of a lapse in government funding, the information on this
website may not be up to date, transactions submitted via the
website may not be processed, and the agency may not be able to
respond to inquiries until appropriations are enacted. The NIH
Clinical Center (the research hospital of NIH) is open. For more
details about its operating status, please visit
cc.nih.gov. Updates
regarding government operating status and resumption of normal
operations can be found at
opm.gov.
Clinical Trials, Phase III as Topic MeSH Descriptor Data 2025
for general design, methodology, economics, etc. of phase III clinical trials; a different heading CLINICAL TRIAL, PHASE III is used for reports of a specific phase III clinical trial
Scope Note
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.
Entry Term(s)
Clinical Trials, Phase 3 as Topic
Drug Evaluation, FDA Phase 3 as Topic
Drug Evaluation, FDA Phase III as Topic
Evaluation Studies, FDA Phase 3 as Topic
Evaluation Studies, FDA Phase III as Topic
Previous Indexing
Clinical Trials (1980-1992)
Public MeSH Note
2008; see CLINICAL TRIALS, PHASE III 1993-2007; for DRUG EVALUATION, FDA PHASE III see CLINICAL TRIALS 1980-1992; for EVALUATION STUDIES, FDA PHASE III see CLINICAL TRIALS 1982-1992
Works about comparative studies to verify the effectiveness of diagnostic, therapeutic, or prophylactic drugs, devices, or techniques determined in phase II studies. During these trials, patients are monitored closely by physicians to identify any adverse reactions from long-term use. These studies are performed on groups of patients large enough to identify clinically significant responses and usually last about three years. This concept includes phase III studies conducted in both the U.S. and in other countries.